Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Yahoo! Finance
PDUFA date of Aug. 22 ; Savara also expects to file MAAs in the EU and U.K. by the end of March. Data from the Phase III IMPALA program showed improvements in DLCO, SGRQ, exercise capacity and surfactant burden, supporting Molbreevi's mechanism of activating macrophages to address the underlying pathophysiology versus the procedure-based standard of care (whole lung lavage). Savara estimates roughly 5,500 diagnosed U.S. patients (~16 per million), has chosen PANTHERx Rare as its exclusive specialty pharmacy and plans a ~30-person field team, and reports $ 264 million cash plus up to $ 150 million in potential non-dilutive funding contingent on FDA approval. Interested in Savara Inc.? Here are five stocks we like better. Savara (NASDAQ:SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer's 36th Annual Healthcare Life Science Conference. Management said the
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Announces Participation in 2026 Citizens Life Sciences ConferenceBusiness Wire
- Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Business Wire
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesBusiness Wire
- Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*Business Wire
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- SVRA's page on the SEC website